Special Lecture

L-2 NMOSD -Where are we in 2014?
Dean Wingerchuk (USA)
Department of Neurology, Mayo Clinic
Neuromyelitis optica (NMO) is an inflammatory CNS syndrome consisting of myelitis and optic neuritis. Diagnostic criteria for NMO have been gradually refined over the past 15 years, most importantly by the discovery of the specific association of NMO with serum antibodies that target the astrocyte water channel aquaporin-4 (AQP4). The disorder is now recognized as an autoimmune astrocytopathy when associated with anti-AQP4 although some patients with the NMO clinical phenotype do not have detectable anti-AQP4. The concept of NMO spectrum disorders (NMOSD) was developed in 2007 to express the broader array of clinical and neuroimaging characteristics associated with anti-AQP4, including 'partial' forms of NMO such as recurrent longitudinally extensive myelitis (LETM) and signature brain MRI lesion patterns. The International Panel for NMO Diagnosis has recently proposed revised consensus NMOSD diagnostic criteria to encompass further advances. These revisions include definitions of core clinical and MRI characteristics related to optic nerve, spinal cord, brain stem, diencephalic, or cerebral presentations and integration with serological data (presence or absence of anti-AQP4). The proposed criteria and their implications for clinical diagnosis and treatment strategies will be discussed along with related issues such as pediatric NMOSD, opticospinal MS, and other antibody associations such as antimyelin oligodendrocyte glycoprotein (MOG).
Main symposium-1
Markers of Progression in MS
L-3 Pathological and MRI markers of deterioration Klaus Schmierer (UK) Centre for Neuroscience and Trauma, Barts and The London School of Medicine and Dentistry
The reasons we keep inspecting samples of MS tissue, mainly in post mortem and sometimes in biopsy tissue, are manifold. Despite the availability of numerous disease models, the pathology of MS remains unique. Novel pathological insights (sometimes important rediscoveries of observations made many decades ago) include the significant degree of axonal damage and loss in acute inflammatory demyelinating lesions, the involvement of the grey matter, meningeal inflammation, and the non-lesional (diffuse) pathology of the MS brain. The pathology of disease deterioration in MS is a game of numbers: inflammation, the accumulation and severity of lesions, the loss of neurons and axons, gliosis -all these features can (some more straightforward than others) be quantified. However, 'deterioration' refers to a clinical scenario, and in order to use pathological observations for the benefit of people with MS (pwMS) translation into clinically applicable this damage. These studies are based on the concept that contact between the cerebrospinal fluid and extracellular matrix of the brain may allow for the diffusion of neuronal breakdown products into body fluids where they can be measured as biomarkers of damage. I will review the current literature on some of the most promising CSF and serum biomarker candidates for axonal injury, with a focus on recent studies of neurofilament-heavy chain levels in serum and CSF of MS cases. This recent work highlights the potential utility of these proteins as prognostic indicators or monitoring tools for axonal injury and disease progression in MS.
PACTRIMS Educational Course
Pitfalls in diagnosing MS and NMO in Asians
L-6 MS mimics in Asians
Chong Tin Tan (Malaysia)
Division of Neurology, Department of Medicine, University of Malaya
This presentation will focus on differentiation between multiple sclerosis (and its related immune demyelinating disorders), with diseases of other aetiologies. The diagnosis of multiple sclerosis (MS) is essentially based on dissemination in space and time, excluding diseases of other known aetiology. It is thus not surprising that there are many mimics particularly during initial presentation, mainly other causes of acute myelopathy, visual failure, and disseminated cerebral white matter lesions. Mimics of acute myelopathy include infective causes such as varicella zoster, dengue, HIV, HTLV-1 and mycoplasma; metabolic causes such as SCDC; vascular and other autoimmune etiologies. Mimics of acute optic neuritis include papilloedema, ischemic optic neuropathy, and Leber hereditary optic neuropathy. Mimics of disseminated cerebral white matter lesions include vascular causes such as leukoaraiosis, cerebral vein thrombosis, PRES, dural AVM, primary CNS angiitis, and CADASIL; tumor lesions such as CNS intravascular lymphoma, infection such as PML, and metabolic causes such as osmotic demyelination syndrome, mitochondrial disease and adult onset leukodystrophy. When making a diagnosis of MS, one should be particularly cautious when there is onset at extremes of age, hyperacute or progressive clinical course, symptoms reflecting predominantly gray matter involvement, imaging showing leptomeningeal involvement, marked mass effect, CSF showing low CSF glucose, and marked pleocytosis. The presence of autoimmune serology markers and CSF OG band should also be interpreted in the overall clinical context. On the other hand, clinical symptoms suggestive of demyelinating pathology include: constricting feeling or tight sensation, sensory ataxia, paroxysmal tonic spasm (PTS), Lhermitte's sign and Uhthoff sign.
L-7 NMO mimics in Asians Naraporn Prayoonwiwat (Thailand) Division of Neurology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University
Remyelination of the central nervous system (CNS) is believed to occur primarily via the generation of new oligodendrocytes derived from oligodendrocyte progenitor cells (OPCs) that reside throughout the CNS parenchyma. Recent studies suggest that neural precursor cells (NPCs) residing within the adult subventricular zone (SVZ) can also contribute to oligodendrogenesis following experimental demyelination. However the relative importance of NPCs versus OPCs during remyelination remains largely unexplored. We adopted a genetic fate-mapping approach to independently trace the progeny of NPC and OPC lineages during the course of CNS remyelination. Nestin-CreER T2 or Pdgfra-CreER T2 mice were crossed with transgenic reporter lines to enable Cre-dependent expression of fluorescent reporter proteins within either the NPC or OPC lineages, respectively. Following tamoxifen-mediated induction of reporter protein expression, mice were challenged with the demyelinating agent cuprizone for six weeks. Upon examination six weeks after cuprizone withdrawal, we quantified substantial numbers of NPCs marked by tamoxifen-induced YFP expression that had migrated into the demyelinated corpus callosum and differentiated into mature oligodendrocytes, particularly in the rostral forebrain across a broad region centered around the dorsolateral corner of the SVZ. Within this region NPC-derived oligodendrocytes outnumbered those generated from OPCs 4.6-fold, indicating that NPCs exhibit a significant competitive advantage over OPCs in this area. NPC-derived oligodendrocytes were also maintained long-term, being detected at similar density at both six and fourteen weeks after cuprizone withdrawal. Independent fate mapping of OPCs during the course of de-/ remyelination revealed that newly-generated oligodendrocytes at six weeks recovery were distributed in a converse manner to NPCderived oligodendrocytes, being localized predominately in the midline and lateral regions of the corpus callosum. Examination of the remyelination capacity of NPC-derived oligodendrocytes revealed that 62% of all nodes of Ranvier adjacent to the SVZ were flanked by at least one myelin paranode generated from an NPC-derived oligodendrocyte. Remarkably, g-ratios of myelinated axons in regions subject to significant NPC-derived remyelination were equivalent to unchallenged controls, and immuno-electron microscopy revealed that NPC-derived myelin was significantly thicker than that generated by pOPCs, irrespective of axonal caliber. We also demonstrate that a reduced efficiency of remyelination in the caudal CC was associated with long-term impairment in the maturation of oligodendrogenic NPCs but only transient delay in pOPC differentiation. Collectively, our data define a major distinct role for NPCs in remyelination, identifying them as a key target for enhancing myelin repair in demyelinating diseases.
Main symposium-2 Cutting Edge of NMOSD Research
L-9
What is Seronegative NMO? Jacqueline Palace (UK)
Division of Clinical Neurology, University of Oxford
The diagnosis of seronegative neuromyelitis (NMO) and NMO spectrum disorder (NMOSD) requires the use of a sensitive aquaporin-4 (AQP4) antibody assay. The assay used varies across the world; with the NMO IgG assay using immunofluorescence being less sensitive than the cell based assay using the M23 isoform of AQP4.
Seronegative NMOSD cohorts differ from those with AQP4 antibodies having a greater preponderance of monophasic disorders, lower female to male ratios, and a greater likelihood of presenting with bilateral optic neuritis and simultaneous transverse myelitis.
Cohorts of NMOSD without AQP4 antibodies consist of a heterogeneous group of conditions, including patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. However some patients are indistinguishable from those with AQP4 antibodies and should be treated in a similar manner.
The AQP4 antibody assays used, the differential diagnoses, and the management strategies in seronegative NMOSD will be discussed.
L-10 NMO Immunopathology
Tatsuro Misu (Japan)
Department of Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine
Neuromyelitis optica (NMO) is an autoimmune disease targeting aquaporin 4 (AQP4), localized mainly at the astrocytic foot processes. Loss of AQP4 and glial fibrillary acidic protein is a pathological hallmark of NMO lesions, suggesting the astrocyte damage and secondary demyelination in NMO. Furthermore, the lesions lacking AQP4 was appeared by passively transferred Lewis rats with human purified IgG from NMO patients, which strongly suggested its autoimmune mechanisms in NMO. T cells including Th17 cell and related cytokines are probably associated with the initial stage of lesion formation, because anti-AQP4 antibody alone could not pass the blood brain barrier (BBB) and needs breakdown of BBB by another specific and non-specific inflammation. In addition, innate immunity such as neutrophil and eosinophil may be the key for the expansion of these NMO lesions, but these phenomena remained to be well-elucidated.
The mechanism of astrocyte damage includes at least two types, complement-related cytotoxic cell lysis and functionally reversible damage. Active lesions in NMO display a wide spectrum of pathology (6 types) even within a single tissue block of an individual patient. Especially, the lesion type 1 reflects the typical perivascular deposition of complement especially at the surface of astrocytes, associated with granulocyte infiltration and astrocyte necrosis and followed by demyelination, which may lead to the global tissue destruction and the formation of cystic, necrotic lesions. In contrast, another lesion type 5 is characterized by clasmatodendrosis of astrocytes, defined by cytoplasmic swelling and vacuolation, beading and dissolution of their processes and nuclear alterations resembling apoptosis, which was associated with internalization of AQP4 and astrocyte apoptosis in the absence of complement activation. Lesion type 6 with a variable degree of astrocyte clasmatodendrosis are found, which show plaque-like primary demyelination that is associated with oligodendrocyte apoptosis, but with preservation of axons.
The existence of orchestrated members in the mechanism of NMO suggests that different mechanisms of tissue injury operate in parallel and needs the lesion-specific therapeutic strategy in this disease.
L-11 AQP4 Immunology in NMOSD
Shuhei Nishiyama (Japan)
Department of Neurology, Tohoku University School of Medicine
Neuromyelitis optica spectrum disorders (NMOSD) is clinically characterized by severe optic neuritis、 longitudinally extensive transverse myelitis and some brain syndromes. Aquaporin 4 (AQP4)-IgG, an NMO-specific autoantibody against the water channel richly expressed in astrocytic endfeet, is a diagnostic biomarker and has a pathogenic potential in causing autoimmune astrocytopathy in NMOSD as shown in experimental studies. In this presentation, an updated overview of the biology of AQP4, humoral and cellular immunity against AQP4, and diverse pathological patterns in NMOSD will be provided. Meanwhile, despite the use of the most sensitive assay of AQP4-IgG, some patients with NMOSD are consistently seronegative. Recently, myelin oligodendrocyte glycoprotein (MOG)-IgG has been detected in a fraction of patients with AQP4-IgG-seronegative NMOSD. Unique clinical and pathological features of MOG-IgG-positive NMOSD will also be reviewed.
Main symposium-3 New Perspectives of Treatment on Idiopathic CNS Inflammatory Disease
L-12 New Perspectives on Inflammatory CNS Disease Therapies Klaus Schmierer (UK) Centre for Neuroscience and Trauma, Barts and The London School of Medicine and Dentistry
This presentation will focus on the treatment of people with multiple sclerosis (pwMS) and clinically isolated syndrome (pwCIS), with some comments on neuromyelitis optica (NMO) and an emphasis on the role of repurposed drugs in the current and future management of people with these conditions. The rising number of available disease modifying drugs (DMD) for people with relapsing MS (pwRMS) has expanded treatment options, however also increased the uncertainty about the best treatment strategy, particularly for colleagues who do not regularly see pwMS in their clinical practice. Broadly speaking, there are two strategies for the use of DMD in pwRMS, early induction or escalation. Assessing and explaining the benefit-risk balance of DMD are key for decision making, and to empower pwRMS to take such decisions jointly with their clinicians poses a major challenge. Even within a seemingly unified healthcare system, such as the NHS in the UK, there is heterogeneity of what is Multiple Sclerosis Journal 2015; 21: (6) 799-838 msj.sagepub.com considered 'best practise', and influenced by restrictions of access to DMD (an issue in many countries). The question of whether or not to treat pwCIS depends on early signs of dissemination, in which case treatment should commence. Whilst there is currently no licensed DMD for pwNMO, various immunomodulatory drugs are being used, and trials with promising molecules underway. The debate whether trials should be placebo-controlled is ongoing. With two exceptions all currently licensed (and some unlicensed) DMD used in pwCIS and pwMS are repurposed drugs, which have served pwMS well for over 20 years since the introduction of beta-interferons revolutionised MS management. Whilst repurposed drugs are thus the mainstay of current MS disease modifying therapy, the more recent discussion about repurposing has focussed on generic drugs that may not only be safe and effective, but also more affordable treatments for pwMS.
L-13
Anti-HMGB1 as Potential Therapeutics for NMO Li-Te Chin (Taiwan) Department of Microbiology, Immunology and Biopharmaceuticals, National Chiayi University, Chiayi City, Taiwan In theory, heavy and light chain components derived entirely from the human origin could be used to assemble mAbs in phage or non-human animals. However, the resultant pairings may not be naturally-occurring and still remain to be immunogenic as indicated in the official FDA labeling information. Therefore, this may not be the best available strategy. Alternatively, a sharp clinical contrast provided by the therapeutic immunoglobulin preparations, and especially intravenous immunoglobulin (IVIg), may well turn out to be optimistic in resolving the problem of immunogenicity. HumOrigin has developed a sitedirected in vitro immunization platform to achieve this goal. High-mobility group box 1 protein (HMGB1) has cytokine activities and mediates systemic inflammation as well as immune responses. In our previous study revealed that plasma HMGB1 level can be used as a marker for neuromyelitis optica (NMO) in which severe inflammatory response is often associated clinically with transverse myelitis and optic neuritis. The role of HMGB1 is possible, given that factors inducing its release, such as extensive necrosis, demyelination, and perivascular macrophage infiltration are common clinical features. The resulting mAbs against the pre-defined epitopes of human high mobility group box 1 (huHMGB1) and that function to abrogate the HMGB1-induced proinflammatory pathway and thus HMGB1 associated-neuropathy and NMO will be discussed. IFN-Beta and other FDA approved DMT drugs are not covered by the insurance, and the high cost has to be borne by patients. Moreover, the relatively low prevalence, paucity of specialized MS centers and long distance travel for individual patients to reach those centers seem to have been challenging. Therefore, like in other resource-poor areas, we need to seek a cost-effective strategy for the management of MS -a chronic devastating disease.
L-14 Long Term MS Management in China
Closing Lecture
L-15 Reviewing a Decade of Discovery in Asia
Ho Jin Kim (Korea)
Research Institute and Hospital of National Cancer Center, Korea
A decade has passed since the first disease-specific autoantibody of CNS, neuromyelitis optica (NMO)-IgG, was discovered. A year later, aquaporin-4 (AQP4) was identified as a target antigen of NMO-IgG. Such breakthrough discoveries initiated dramatic advances in our understanding of NMO, which has long been considered a subtype of multiple sclerosis (MS), so-called "optic-spinal MS". However, a series of clinical, pathological, immunological, and imaging studies have clarified that NMO is distinct from MS and is now considered an autoimmune astocytopathic disease. Additionally, the identification of anti-AQP4 antibodies in patients with only one of either index events of NMO or with recently recognized pattern of brain abnormalities, indicate a broader clinical phenotype of this disorder, so-called "NMO spectrum disorder (NMOSD)".
The past decade has witnessed marked advance in MS therapeutics, too. Ten years ago, interferon-beta was the only available therapy in most of Asian countries. However, new therapies have been continuing to emerge and now more than 10 MS diseasemodifying drugs are approved, although the availability of these drugs varies among countries. The therapeutic environment of MS has changed and is likely to change continuously.
In this talk, I'll review the discoveries and advances in our region over the past 10 years.
Objective: To investigate cognitive function and MRI-measured brain volume and cortical thickness in patients with neuromyelitis optica spectrum disorder (NMOSD) in comparison with those in patients with multiple sclerosis (MS). Methods: Forty-three patients with NMOSD, 34 with MS, and 31 normal controls (NCs) underwent neuropsychological tests and MRI examination. Cognitive impairment was considered if at least three cognitive domains were inferior to the 5 th percentile for NCs. MRI measures included global brain volume, deep gray matter (GM) volume, and cortical thickness. Results: Cognitive impairment was seen in 28% of NMOSD and 53% of MS patients (P = 0.040). Visual memory (37%) and information processing speed (33%) were the most commonly impaired functions in NMOSD. In contrast, verbal memory (56%) was the most commonly impaired function in MS, followed by visual memory (41%) and information processing speed (41%). Performance scores of verbal memory were significantly different between NMOSD and MS, while no such differences were observed in other scores. MS patients exhibited more widespread and greater deep GM volume reduction and cortical thinning, while NMOSD patients showed regional GM volume reduction and cortical thinning. Brain volume and cortical thickness were not significantly different between NMOSD patients with and without cognitive impairment, whereas cortical thinning was associated with cognitive impairment in patients with MS (P = 0.027). Conclusion: Cognitive impairments were less common and less extensive in NMOSD patients than MS patients. Changes in brain volume and cortical thickness did not add to the predictive value for cognitive impairment in NMOSD. Objective: To collect long-term, real-life data on safety, patientreported QoL, and physician-reported walking ability in MS patients treated with PR-fampridine. Methods: LIBERATE is an observational study in patients beginning treatment with PR-fampridine 10 mg twice daily in routine clinical practice. Data were collected at enrollment (baseline) and during follow-up visits for 6 months. Patients who discontinued treatment were encouraged to stay in the study (patients off treatment). Endpoints included incidence of AEs, physician-assessed Clinical Global Impression of Improvement (CGI-I) of walking ability and patient's assessment of MS using the Multiple Sclerosis Impact Background: In the phase 3 CARE-MS I study (NCT00530348), alemtuzumab significantly reduced relapse rate over subcutaneous interferon beta-1a (SC IFNB-1a), with manageable safety over 2 years. Objectives: Examine 4-year efficacy/safety of alemtuzumab in patients treated with alemtuzumab during CARE-MS I, and 2-year efficacy/safety in patients switched to alemtuzumab in the extension study (crossover cohort; NCT00930553). Methods: In CARE-MS I, treatment-naive patients with active RRMS received 2 courses of alemtuzumab (12 mg/day intravenously on 5 consecutive days and on 3 consecutive days 12 months later) or SC IFNB-1a (44 μg 3 times/week). In the extension study, patients could receive as-needed alemtuzumab retreatment ≥1 year apart or approved disease-modifying therapy (DMT). Crossover patients received 2 alemtuzumab courses (5 days, then 3 days), 12 months apart. Results: The extension enrolled 349 (95%) alemtuzumab-treated patients from the core study. Through 4 years, 73% received only 2 annual courses, while 21% and 5% received 1 or 2 additional courses, respectively; <5% of patients received another DMT during extension. Nine patients (3%) discontinued from the study, none due to adverse events (AEs). Among SC IFNB-1a-treated patients, 144 (83%) entered the extension and 132 (92%) received 2 courses of alemtuzumab. There were 8 withdrawals (6%) in the crossover group during the 2-year extension period, none due to AEs. Efficacy and safety data will be reported for both treatment cohorts. Conclusions: Most patients treated with alemtuzumab did not require additional courses or other DMT during the 2-year extension; study discontinuation rates were low after alemtuzumab treatment. Background: In the last 2 decades, intensive immunosuppression followed by autologous stem cell transplantation (ASCT) has been proposed as a possible strategy for treatment of severe immune-mediated disorders, including multiple sclerosis (MS). Objective: To review the outcome of ASCT for MS in Western Australia. Methods: Eligibility criteria for ASCT were (1) progression of sustained disability with expanded disability status scale (EDSS) score increase of more than 1/10 over a 12 month period, (2) advanced MS with threatened loss of ambulation and (3) rapidly progressive disease not adequately assessed by EDSS. Stem cell mobilization was with cyclophosphamide (CY) 2g/m 2 and granulocyte-colony stimulating factor 5ug/kg bd. conditioning chemotherapy was with CY 50mg/kg and rabbit antithymocyte globulin 1mg/kg days -5 to -2. Patients were assessed at 3, 6, 12 and 24 months post-transplant. Results: Fourteen patients underwent ASCT. Median age was 47 years; median time from diagnosis to transplant was 12 years. Diagnosis at transplant was secondary progressive MS (12), primary progressive MS (1) and neuromyelitis optica (1). About half the cohorts were neurologically stable at 24 months while the remainder had clinically relevant neurological deterioration. Two patients had meaningful improvement in bladder function. Follow-up MRI showed no Gd-enhancing lesions, but two patients developed new cerebral lesions on T2 weighted imaging. Conclusion: In this group of patients with advanced MS, neurological function 24 months post-ASCT was essentially stable in half the cohort while the remainder experienced clinical progression. It is not possible to conclude whether ASCT altered the natural history of the disease. Background: Diagnosis and treatment decision-making in multiple sclerosis (MS) greatly depend on magnetic resonance imaging (MRI). MS plaques in conventional MRI are defined as T2-hyperintense lesions. The major limitation of T2-hyperintensity is that it cannot discern remyelinated lesions from chronic demyelinated lesions. A sensitive measure to visualize myelin status is mandatory for a better clinical practice. Objectives: We developed a novel q-space imaging-based MRI method named "Myelin Map", and we have previously shown the ability of Myelin Map to differentiate remyelinated T2-lesions among MS plaques. In the current study, we aimed to testify the feasibility of Myelin Map to monitor demyelination and remyelination in a longitudinal axis in selected MS cases. Methods: Four MS cases without clinical deterioration during the observation period (two relapsing-remitting (RR) MS and two secondary progressive (SP) MS), with or without treatment were included in the study. Myelin Map was performed with a 3-tesra MR scanner twice at an interval of 5-9 months for each patient. Results: One early RRMS patient showed no interval difference in Myelin Map after 5 months. The other RRMS patient revealed a few newly-remyelinated lesions after 9 months. One SPMS patient showed both newly-remyelinated and demyelinated lesions after 9 months, whereas the other SPMS patients revealed a few newlyremyelinated lesions but no new demyelinated lesions after 7 months. Conclusions: Our results suggest that there are inter-individual differences in remyelination capacity among MS patients. Myelin Map may be a useful tool to monitor myelin status in MS and further studies are warranted. To assess the effect of natalizumab on disability changes during AFFIRM; a randomised, placebo-controlled trial of relapsing MS patients. Methods: EDSS assessments were performed every 3 months. EDSS scores were plotted over time for each patient (natalizumab, n=627; placebo, n=315). The area under the EDSS/time curve was calculated then the sum of the patient's baseline EDSS score and trial duration was subtracted. The result was the area under the curve (AUC) in EDSS years. A positive AUC indicated worsening in EDSS; a negative AUC indicated improvement. Least squares mean AUC, adjusted for baseline EDSS, was compared between groups using ANCOVA. Patient proportions with AUC ≥1.0, ≥1.5, or ≥2.0 EDSS years were compared by Fisher's exact test. Results: Natalizumab patients had a net improvement in disability over time ; placebo had a net worsening (+0.33 EDSS years; P<0.0001). Compared with placebo, natalizumab improved mean AUC by 0.53 EDSS years in patients with EDSS ≥2.5 (P<0.01) and by 0.44 EDSS years in patients with EDSS <2.5 (P<0.001). Natalizumab decreased the risk of net worsening in disability of ≥1.0, ≥1.5, and ≥2.0 EDSS years by 44% (P<0.001), 53% (P<0.001), and 55% (P<0.001), respectively. Conclusions: AUC measurements of EDSS are useful to compare MS disability changes. Natalizumab-treated patients had less disability and were less likely to have worsening disability compared with placebo over time. Background: Although neuroaxonal injury is recognised as the primary driver of disability in multiple sclerosis, there is no universally acknowledged gold standard for the measurement of neurodegeneration. Objectives: Characterise thalamic and whole brain volumetrics, and changes in proton magnetic resonance proton spectroscopy ( 1 H-MRS) data of normal appearing white matter (NAWM), to elucidate their role as potential biomarkers of disease progression in relapsing remitting multiple sclerosis (RRMS). Methods: We studied 68 RRMS patients over 12 months with a mean Expanded Disability Status Scale (EDSS) score of 1.9 at baseline. Clinical assessment, 3.0T MRI, and NAWM 1 H-MRS were performed at 0, 3 and 12 months. Linear mixed models examined the relationship between longitudinal changes in whole and thalamus volumes, NAWM neurometabolite concentrations and disability. .044]. Levels of NAA-Cr did not vary significantly over the 12 month period and were not associated with decreasing whole brain, thalamic volumes or worsening EDSS scores. Conclusions: Thalamic and whole brain volumes reductions correlate with worsening disability in RRMS over a 12 month period. Thalamic volumetrics were found to be a more robust marker of disease progression than NAWM NAA-Cr levels over a short clinical timeframe. Background: Clinically isolated syndrome (CIS) such as optic neuritis, brainstem or spinal cord syndromes may represent the initial phase of multiple sclerosis (MS) but not all patients will convert to MS. The proportion of patients reported to convert to MS varies between 30-75% depending on the cohort. Objective: To identify predictors of conversion to definite MS in patients with CIS, in the geographically isolated predominantly Anglo-Celtic population of Western Australia.
O-
Multiple Sclerosis Journal
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Multiple Sclerosis Journal
O-15 Predictors for The Conversion of Clinically Isolated Syndrome to Multiple Sclerosis in Western Australian
Methods:
The predictive values for conversion to MS of demographic, clinical and magnetic resonance imaging (MRI) variables in patients who presented with CIS were studied. Results: A total of 140 patients with average onset age of 38 ± 12 years were included in this study. MS was diagnosed in 86 patients (61%) and 54 patients (39%) remained as CIS. The mean age of onset was significantly lower in the MS conversion group compared to remaining CIS (36 ± 10 vs 40 ± 13, respectively). The mean time to conversion was 24.9 ± 29.2 months. 56.5% of patients converted to MS based on clinical relapse, while 43.5% based on MRI results. We identified two predictors of MS diagnosis: age at onset ≤ 35 years (p = 0.027) and initial MRI having lesions suggestive of MS (p = 0.014). Conclusion: Based on the results, a younger age of onset and suggestive MRI lesions are strong predictors for the conversion to MS. These results are similar to those in other Anglo-Celtic cohorts. Previously, Iran was considered to have a low prevalence rate of multiple sclerosis (MS), but this rate has significantly increased over time. We think that gathering a number of variable explanations (genetic and environmental factors) is responsible for the increased incidence and prevalence of MS in Iran.
O-16
1. Improvement in diagnostic tools such as MRI and increased their availability, increased awareness of physicians and patients regarding the symptoms of the disease and improved probability of survival may be among the responsible reasons.
2. Preponderance of young population in Iran during the recent years may be a remarkable factor for this increase rate as MS mainly entangles young adults.
3. As vitamin D deficiency is highly prevalent among Iranians, it is one of the possible major environmental candidates responsible for high prevalence of MS in our country. Background: Standing balance is one of the most important and essential activities of daily life, which is named "postural control" (1). Poor Balance, fear of falling and mobility limitation may lead to change in the quality of life, especially if injurious falls occurred (2,3). Imbalance is commonly seen in elderly people, patients with peripheral neuropathy disorders and also in multiple sclerosis patients. Studying the mechanisms which contribute to postural control disorders would help to explain interventions aimed to reduce the rate of loss of postural control and also aimed to rehabilitate these patients.
Multiple Sclerosis Journal 2015; 21: (6) 799-838 msj.sagepub.com
Objective: The purpose of this review study was to investigate the effect of somatosensory impairments on postural control of people with multiple sclerosis. Method: Papers from 1950 to 2014 were examined by performing a systematic search of electronic databases including Google scholar and PubMed. Keywords used in this work include various combinations of multiple sclerosis, balance, somatosensory and their synonyms. At last, titles and abstracts were estimated and 41 literatures were accepted and grouped into two categories. One) studies which examined the impact of somatosensory on balance in healthy controls (n=41). Two) studies which examined the impact of somatosensory on balance in MS people (n=7). Results: studies demonstrated that sensory feedbacks from cutaneous receptors of foot sole play an important role on regulating balance of healthy subjects. In these studies, researchers had investigated the postural control of healthy controls by applying interventions such as local anesthesia, ice immersion approach (cooling), placing a cuff on the leg, ischemic block techniques, changing support surface or even applying vibration.
Conclusion:
We know maintaining balance requires integration of vestibular, visual, and somatosensory information and multiple sclerosis can cause malfunctions of these systems (4, 5). Also as the number of systems involved was greater, imbalance became greater in these patients (6). According to this review, balance of MS patients was lower than healthy controls and they act weaker than healthy people in perturbation tests. These studies showed that reducing light touch pressure, proprioception and vibration caused by disruption of ascending nerve fibers (myelin removal in the posterior columns of the spinal cord) and reducing nerve conduction velocity in somatosensory system caused abnormal postural responses in these patients (6). But more studies are needed in this regard. Introduction: Balance disorder is one of the most common impairment in patients with multiple sclerosis. The results of some studies indicated the effect of sensation on balance in these patients. Although multiple sclerosis is a systematic disease and affects the total body, but these studies focused on lower limb. However, researchers have shown the effect of sensation of upper limb on balance. Objective: The aim of this study was to determine the prevalence of sensory impairment in limbs and its relation with balance and quality of life in patients with multiple sclerosis. Methods: In a cross-sectional study, 82 patients (age: 36.9±9 years) and 30 healthy subjects (age: 32/1± 9/5 years) were included. The prevalence of sensory impairments was assessed based on Rivermead Assessment Somatosensory Perception (RASP) technique, balance was assessed by using of functional reach test (FRT) and timed up and go (TUG), and quality of life(QoL) was assessed by 36-item Short-Form Health Survey (SF-36).statistical analysis was performed with SPSS software.
P-
Results: Based on this study the prevalence of sensory impairments in patients with multiple sclerosis was 71/8 percent (66/7% properioception and 60/8% light touch), 61/5 percent in lower limb (66/7% properioception and 60/8% light touch) and 54/4 percent in upper limb (33/3% properioception and 43% light touch) (p<0.01). Compared to control group, balance showed a significant reduction in these patients. There was correlation between FRT and total body (r=0/3, p<0/01), lower limb (r=0/4, p<0/01) and upper limb (r=0/3, p<0/01) sensory impairment. TUG also had significant correlation with sensory impairment, (total body=-0/4, lower limb=-0/6, upper limb=-0/4) (p<0.01). Results indicated a significant reduction in quality of life in MS patients compared with the control group (p <0/05) and their sensation was directly associated with QoL scores (r=0/3, P <0.01). In this study correlation between proprioception and QoL was more remarkable. Conclusion: According to high prevalence of sensory impairments in people with multiple sclerosis and its correlation with balance and QoL, interventions with the aim of improving sensation may improve balance and QoL and also it may minimize the secondary complications such as risk of falling and fracture. Chronic pain is a major source of disability in patients with multiple sclerosis (MS) and neuromyelitis optica (NMO). Few studies examined the association of chronic pain and quality of life (QOL) in Chinese patients. We examined the prevalence of chronic pain and its association with QOL in a cohort of Chinese patients with MS or NMO. From the Hong Kong Multiple Sclerosis Registry, we recruited subjects for structured interview if 1) aged between 18-70, 2) diagnosed MS/NMO/related disorders for >1 year, 3) experienced impaired sensory function. Subjects with pain due to other neurological, systemic or psychiatric diseases were excluded. Brief Pain Inventory Short Form (BPI) and Multiple Sclerosis Quality of Life Instrument (MSQOL-54) were used to assess pain score and QOL respectively. Of 17 subjects recruited, mean onset age was 30±13 years and disease duration 10±6 years. 9/17 (53%) had MS and 7/17 (41%) had NMO. 13/17 (77%) experienced pain. 11/13 (85%) had chronic pain, who had a significant worse pain interference score compared to subjects without chronic pain (4.3 vs. 0, p<0.1). Chronic pain is associated with poorer QOL (MS: 56.7 ± 24.9, NMO: 55.2 ± 33.1, non-chronic pain 85.8 ± 19.5; p<0.05). Mean pain interference is negatively associated with QOL in physical (r= -0.823, p<0.01) and mental (r= -0.803, p<0.01) health functioning. Chronic pain is prevalent among Chinese patients and is associated with poorer physical and mental health functioning. 
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P-8 Identifying a Minimally Important
Methods:
We evaluated the hospital files of 63 MS patients retrospectively. They were screened for thyroid function (free-T3, free-T4, thyroid stimulating hormone (TSH)). In 23 MS patients anti-thyroid peroxidase (anti-TPO) and in 6 MS patients anti-thyroglobulin antibodies were studied for autoimmunity. Results: All of the patients had normal thyroid functions and autoimmune markers. Conclusions: In content to some previous studies we could not be able to detect any thyroid diseases in patient with MS. Background: Autoantibodies are more frequently detected in patients with multiple sclerosis (MS) than in the general population. However, the role of autoantibodies in the pathogenesis of MS and their associations with autoimmune comorbidity are still unclear. Objective: The aim of this study was to determine the frequency of autoantibodies in Korean patients with MS and evaluate clinical associations with autoimmune comorbid diseases. Methods: A total of 128 consecutive patients with MS were enrolled. The seropositivity of following autoantibodies was investigated: ANA, SS-A, SS-B, antiphospholipid, anti-TPO, anti-Tg, and RF. Presences of other autoimmune diseases were evaluated in seropositive patients. Results: Of the 128 patients, 79 were female and 49 were male. Autoantibodies to at least one autoantigen were detected in 44 patients (F/M=24/20). ANA (21%) and SS-A (10%) were most frequently accompanied. In only 3 patients (2.3%), the presence of autoantibodies was associated with the clinical features of connective tissue diseases. Conclusion: Autoantibodies were seropositive in about 35% of Korean patients with MS, which was comparable to the prevalence previously reported for MS in Caucasian populations. Presence of autoantibodies was not associated with systemic autoimmune diseases in most seropositive patients.
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Anti-Double Stranded Dna, Anti-Nuclear Antibodies and Subtypes in Multiple Sclerosis Patients Demirkaya Şeref*, Çetiz Ahmet*, Öz Oguzhan*,
*Gülhane military Medical Faculty, Neurology Department
Background: Many autoimmune disorders affecting central nervous system (CNS) may mimicking MS. In this aspect it is important to distinguish demyelinating diseases from other autoimmune disorders.
Objectives:
We aimed to determine anti-ds DNA antibodies, antinuclear antibodies (ANA) in MS patients. Methods: We evaluated the hospital files of 70 MS patients retrospectively regardless of their clinical condition and treatment options. We noted the anti-dsDNA antibodies, ANA, anti-Ro antibodies (anti-SSA), anti-La antibodies (anti-SSB), anti-Sm/RNP antibodies, anti-Sm antibodies, anti-Scl-70 antibodies,, anti-Jo1 antibodies. None of the patients had rheumatological diseases. Results: 20 of 70 patients had positive ANA results. Conclusions: ANA in patients with MS do not address any disease and it is controversial whether checking ANA levels or not. 
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Conclusions:
To conclude, we demonstrated that different types of CIS patients were characterized by a different vitamin D3 status. However, this observation should be interpreted with caution and additional studies with larger sample sizes will be required to confirm whether this association is accurate and also explain mechanisms for such finding.
Poster Session 4 MS Neuroimaging
Introduction: MS is an inflammatory demyelinating disease affecting both white matter (WM) and grey matter (GM). Our aim was to investigate whether cortical grey matter atrophy is associated with clinical, cognitive diasability and retinal nerve fiber layer (RNFL) thicknes in patients with multiple sclerosis. Methods: We enrolled 40 consecutive MS patients and 20 normal controls undergoing 3T brain MRI, OCT and neuropsychological testing. Diffusion Tensor MRI (DTI) and tractography were performed. Neuropsychological test includes Paced Auditory Serial Addition Test (PASAT), the Symbol Digit Modalities Test (SDMT) and verbal fluency test (VFT) respectively. Results: In DTI-FT measurements, FA values of cortical GM areas were lower in all MS patients and MD values of GM areas were higher in MS patients (p=0,0001). GM volume values were lower in MS (p=0,0001). RNLF thickness averages of bilateral superior and temporal quadrants in MS patients were statistically lower (p=0,001). No correlation was found between GM volume and RNFL thickness. No correlation was determined between grey matter volume values of patients group and PASAT scores (p>0,05). A negative correlation between GM volume values of patients group and VFT was determined (r=-0,340 p=0,032).
Conclusion:
The results confirmed that there was significant difference in cortical GM DTI-FT and RNFL thickness between MS and controls. Whereas DTI showed significant GM involment in MS we could not find correelation with PASAT scores. GM involment in MS by unconventional MRI techniques such as DTI-FT and OCT, will make remarkable contributions to the evaluation of grey matter involvement.and axonal degenaration in MS. Introduction: Deep gray matter (DGM) atrophy has been reported in patients with multiple sclerosis (MS). Our aim was to investigate whether a particular pattern of deep GM atrophy is associated with cognitive impairment in patients RRMS. The relationship between diffusivity markers, and atrophy of the deep GM structures, as well as clinical status of the patients was also explored. Methods: We enrolled 40 consecutive MS patients and 20 normal controls, 3 Tesla Diffusion Tensor MRI and tractography were performed including anatomic and DTI acquisitions. Volumes, mean fractional anisotropy (FA), and mean diffusivity (MD) of the DGM structures were assessed. Neuropsychological testing contributed measures of using the Paced Auditory Serial Addition Test (PASAT), the Symbol Digit Modalities Test (SDMT) and verbal fluency test (VFT) respectively. Results: MD was significantly decreased in the right/left thalamus of patients with MS compared with controls (p=0.0001), FA was significantly increased in the left thalamus. (p=0.006). There was no significant differences of FA in right thalamus and MD in right putamen, left globus pallidus (p>0,05). There was significant differences of caudate nucleus FAand MD patients with MS compared controls (p=0,005, p=0,001). Putamen right/left FA significantly decreased in MS group compared to controls (p=0,0001). There was significant correlation of PASAT scores and left thalamus and caudate nucleus FA and MD in MS patient compared to controls. Conclusıons: We confirm the significant role of thalamus and caudate nucleus involment in MS-associated cognitive disorder, and further report that DGM involment as detected by DTI corralated with clinical cognitive deficits. Background: Brain 1 H-magnetic resonance spectroscopy (MRS) indicates occult injury to the normal-appearing white matter (NAWM) in relapsing remitting multiple sclerosis (RRMS). Reduced N-Acetyl Aspartate (NAA) is consistent with neuroaxonal dysfunction and/or loss, elevated choline (Cho) suggests myelin breakdown and elevated myo-inositol (MI) is at least partially attributable to astrogliosis. However, the relationship between specific metabolite change/s in the NAWM and global white matter tract integrity is yet to be determined. Objectives: Investigate whether changes in NAWM NAA/Cr, MI/Cr or Cho/Cr ratios are related to changes in global white matter tract integrity as measured using fractional anisotropy (FA), radial diffusivity (RD) and axial diffusivity (AD) in RRMS. Methods: Eighty six RRMS patients underwent magnetic resonance imaging to obtain whole-brain diffusion weighted images, a T2-weighted fluid-attenuated inversion recovery (FLAIR) sequence and 1 H-MRS measures. Tract based spatial statistics investigated the relationship between diffusivity metrics and metabolite ratios. Significance was set at p < 0.01 TFCE-corrected. Results: Reduced NAWM NAA/Cr was correlated with global FA reductions and AD/RD increases. Increased MI/Cr ratio correlated with reduced FA and increased RD. Controlling for T2 lesion load, NAA/Cr was only associated with decreased FA. Conclusions: In RRMS patients, MRS of the NAWM is a sensitive biomarker of global white matter integrity. In particular, evidence of axonal injury in the NAWM correlates with global white mater fractional anisotropy. Additionally, increased white matter tract RD in subjects with high NAWM MI/Cr may indicate that non-lesional astrogliosis is primarily a function of global myelin integrity.
P-16 Deep Gray Matter Involvement in Multiple Sclerosis
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Multiple Sclerosis Journal 2015; 21: (6) 799-838 msj.sagepub.com Objective: To explore the integrity and connectedness of sensorimotor network (SMN) in local and global level in remitting MS patients, using voxel-based degree and eigenvector centrality (DC and EC) analysis. Methods: After the rs-fMRI data preprocessing using DPARSFA (http://www.restfmri.net) based on Matlab-2012a: (1) DC and EC maps were calculated and compared between the remitting MS and healthy control (HC) (n= 34), respectively; (2) DC and EC maps were also compared in paired relapsing(rapid-onset) MS and remitting MS (n=11); (3) in remitting MS group, linear regression analysis was conducted for evaluating the relationship between clinical metric and voxel-wise centrality and rest-state functional connectivity of the obtained abnormal regions.
Results:
The main finding of the remitting MS show that: (1) compared with HC, not only reduced DC in the premotor, supplementary motor and related-integrated regions, which reflects the cerebral adaptive alterations, also increased DC in primary motor cortex (right M1) and parietal-integrated regions positively correlated with EDSS, which is less efficient in motor information processing; (2) compared with relapsing MS, increased DC in the bilateral M1/S1, and left operculum parietale/ temporoparietal junction, which reflects the rapid-onset central motor plasticity, also reduced DC in the premotor, supplementary motor area/ dorsal premotor, operculum and parietal pathway, which reflects a rapid-onset plasticity reshaping, trends toward subsides. (3) The alterations of EC similar to DC, when compared with HC or relapsing MS. Conclusions: These findings in both local and global connectedness provide deeper insights about plasticity of SMN in remitting MS. Objective: To investigate the "small-world" property of default mode network (DMN) in relapsing-remitting multiple sclerosis (RRMS) group, using a graph theoretical analysis based on resting-state fMRI (R-fMRI). Methods: Twenty-four MS patients remain in remitting stage and 24 age-, and sex-matched healthy controls were examined by R-fMRI and 3D-T 1 WI on Trio-3.0-Tesla-MRI. The R-fMRI data was preprocessing, 20 regions of interest within DMN was defined, and calculated by Pearson's correlation. Graph theoretical analysis was implemented and compared the property of binary functional network "small-world" network. Furthermore, the relationships associated with clinical were examined. Results: We successfully construct functional network in DMN, and observe the "small-world" characteristics in remitting MS patients. In the range of network densities (D min : 0.01: 0.48; D min = 0.42), compare with control subjects, the patients have non-significantly smaller normalized clustering coefficient, larger normalize path length, and non-significantly smaller "small-world" index (P > 0.05); but a larger clustering coefficient (P = 0.031) in the left posterior cingulated cortex (PCC) on the network threshold at D min . We also compare the area-under-a-curve (AUC) for clustering coefficient measure curves of the left PCC (density range of 0.42: 0.01: 0.48) between two groups. The AUC result is similarly with the D min result (P = 0.031). Negative correlation is observed between the clustering coefficient of left PCC and the Paced Auditory Serial Addition Test (PASAT). Conclusions: The DMN has "small-world" property in the remitting MS patients. The significantly increased clustering coefficient was observed in the left PCC, which may be a "side effect". Objective: To explore the effective connectivity of default mode network (DMN) in relapsing-remitting multiple sclerosis (RRMS) group and compare with matched healthy control subjects, using a resting-state granger causality analysis (GCA). Methods: Twenty-four patients with RRMS and 24 age-, and sexmatched healthy controls were examined by resting-state fMRI (R-fMRI) and 3D-T1. The R-fMRI data preprocessing and processing was performed using DPARSFA (http://www.restfmri.net) based on Matlab 2012a; the spatial patterns of DMN was constructed by seed-based (posterior cingulate cortex) correlation analysis, then 6 principal components of DMN was selected for more GCA. To further analyze the correlations between effective connectivity and clinical parameter in patients group. Results: In this study, we observed driving hub in medial prefrontal cortex of both groups. Compared with control group, RRMS groups exhibited an altered signed-path coefficient and direction between the left and right inferior parietal lobules (t=3.071, P=0.004), the left inferior parietal lobule and the right middle temporal gyrus (t=2.053, P=0.046). Expanded disability status scale (EDSS) significant positive-related with the signed-path coefficient between left and right inferior parietal lobule (P=0.045), left inferior parietal lobule and right middle temporal gyrus (P=0.020), respectively. The correlation were not observed between the altered signed-path coefficient and the paced auditory serial addition test (PASAT), brain parenchymal fraction (BPF), modified fatigue impact scale (MFIS), total white matter lesion loads (TWMLL) (P : 0.187-0.804). Conclusions: These findings provide evidence that abnormal effective connectivity between principal components of DMN in RRMS patients. Background: Approximately 3-5% of multiple sclerosis (MS) patients have disease onset during childhood. Although regularly used in children, neither basic nor escalation disease modifying therapy (DMT) approved for adult MS has been evaluated by controlled trials in children. Objective: Here we present the design of PARADIGMS, a global study of fingolimod versus intramuscular interferon beta-1a (IFNβ1aIM) in paediatric MS. Methods: PARADIGMS is a 24-month, randomised, doubleblind/double-dummy, active-controlled, multicentre study in paediatric MS patients aged 10-17 years. Primary objective is to evaluate the efficacy of fingolimod versus IFNβ1aIM in reducing relapse frequency. Other objectives: evaluation of efficacy on MRI parameters, fingolimod safety/tolerability and pharmacokinetics assessment. Key inclusion criteria: 1 relapse in previous year/2 in previous 2 years (with/without DMT) and Expanded Disability Status Scale score 0-5.5. Key exclusion criterion is active/chronic immune system disease other than MS. Results: In phase 3 studies, annualised relapse rate (ARR) on fingolimod was low irrespective of age, whereas control groups (placebo/ IFNβ1aIM) showed higher ARR in young adults' versus overall control groups. The relative treatment effect of fingolimod versus controls was consistently higher in young adult patients versus overall study populations. This information was used for making sample size assumptions for the paediatric study. Approximately 190 patients will be randomised to receive fingolimod/ IFNβ1aIM (1:1). Conclusions: PARADIGMS will be the first prospective, randomised, controlled study to evaluate therapeutic potential of a DMT in paediatric MS. PARADIGMS is recruiting globally.
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Poster Session 5 MS Treatment
Background:
Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting MS that has consistently demonstrated efficacy in clinical and magnetic resonance imaging (MRI) outcomes. Steady state plasma concentrations of teriflunomide are reached at 3-3.5 months. Objective: to determine whether teriflunomide provides protection from disease activity before reaching steady state levels using data from the phase 2 study (NCT01487096) and phase 3 TEMSO (NCT00134563), TOWER (NCT00751881), and TOPIC (NCT00622700) studies. Methods: Nelson-Aalen estimates were used to assess the onset of teriflunomide efficacy on relapses (pooled TEMSO/TOWER and TOPIC). MRI analyses were performed every 6 weeks until Week 36 (phase 2 study), or at Weeks 12, 24, and 48 (TOPIC). Blood samples were taken at randomization, every 2 weeks for 24 weeks, then every 6 weeks until treatment end for the determination of neutrophil and lymphocyte counts (pooled phase 2, TEMSO, TOWER, and TOPIC). Results: Efficacy onset of teriflunomide 14 mg or 7 mg on relapse was observed within 6 weeks vs placebo. In the phase 2 study, combined unique active lesions (UALs) were reduced for teriflunomide after 6 weeks vs placebo, reaching significance at Week 12. In TOPIC, teriflunomide 14 mg reduced total lesion volume (significant reduction) and UALs by Week 12 vs placebo. Mean neutrophil and lymphocyte counts decreased within 6 and 12 weeks, respectively, and remained within normal levels. Conclusions: Efficacy onset of teriflunomide on relapses, MRI outcomes, and laboratory parameters is evident shortly after treatment initiation, before plasma steady state concentrations are reached. 
P-29 MRI Outcomes in Patients With
Background:
Teriflunomide is a once-daily oral immunomodulator for relapsing-remitting MS. The phase 3 TOPIC study (NCT00622700) evaluated the efficacy and safety of teriflunomide in patients with first clinical episodes suggestive of MS and magnetic resonance imaging (MRI) scan showing ≥2 T2 lesions. Teriflunomide significantly reduced the risk of relapse confirming clinically definite MS. Objective: To report the effects of teriflunomide 14 mg on MRI activity. Methods: A total of 614 patients received once-daily teriflunomide 14 mg or 7 mg, or placebo. MRI was performed at screening and 12, 24, 48, 72, and 108 weeks (predefined main time point for analysis) and processed at a centralized analysis centre.
In the 2-year CARE-MS II study (NCT00548405), alemtuzumab had superior efficacy over subcutaneous interferon beta-1a (SC IFNB-1a), with manageable safety. Objective: To examine 4-year efficacy/safety of alemtuzumab in patients treated with alemtuzumab during CARE-MS II, and 2-year efficacy/safety of patients who switched from SC IFNB-1a to alemtuzumab in the extension study (crossover cohort). Methods: In CARE-MS II, patients with active RRMS who relapsed on prior therapy received 2 alemtuzumab courses (12 mg/day intravenously on 5 consecutive days and on 3 consecutive days 12 months later) or SC IFNB-1a (44 μg 3 times/week). In the extension study (NCT00930553), alemtuzumab-treated patients could receive as-needed re-treatment or approved disease-modifying therapy (DMT). Crossover patients received 2 alemtuzumab courses (5 days, then 3 days) 12 months apart. Results: The extension enrolled 393 (93%) patients from the core study alemtuzumab arm. Through 4 years, 68% received only 2 courses, while 24% and 7% received 1 or 2 additional courses, respectively; 5% of patients received another DMT during the extension. Twenty-five patients (6%) discontinued from the study, none due to adverse events (AEs). Among patients who received SC IFNB-1a, 146 (83%) entered the extension, 131 (90%) received 2 courses of alemtuzumab. There were 7 withdrawals (5%) in the crossover group during the 2-year extension, 1 due to AE. Efficacy and safety data will be reported for Year 2 of the extension for both treatment cohorts. Conclusions: Most alemtuzumab-treated patients did not require additional courses or other DMT during the extension; study discontinuation rates were low. Background: Alemtuzumab showed superior efficacy over subcutaneous interferon beta-1a and manageable safety in 3 randomised studies. Alemtuzumab is eliminated from the body 1 month after administration. Before elimination, there is potentially drug transfer to fetus during gestation and postpartum in breast milk. European label guidelines recommend contraception in women for ≥4 months after treatment. Objective: To report pregnancy outcomes in the alemtuzumab MS clinical development program. Methods: In phase 2 and 3 studies (NCT00050778; NCT00530348; NCT00548405), and their extension (NCT00930553), patients received 2 or more courses of alemtuzumab (12 or 24 mg/day intravenously on 5 consecutive days at baseline, and on 3 consecutive days ≥12 months later). Contraception was required during core studies and for 6 months after extension study treatment, but patients becoming pregnant could remain on study. Results: As of October 17, 2013 (N=1486), 139 pregnancies occurred in 104 patients (67 live births, 14 elective abortions, 24 spontaneous abortions, 1 stillbirth, 4 unknown outcomes, and 29 ongoing). Most pregnancies (133/139) occurred >4 months after last alemtuzumab dose. Spontaneous abortion rate was agerelated. Serious adverse events (SAEs) occurred in 11 fetuses/ infants; each SAE was unique. Grade 4 thyrotoxic crisis occurred in a 21-day-old, full-term infant whose mother developed Basedow's disease during pregnancy; infant recovered after treatment. Two elective abortions followed fetal defect SAEs. No pattern in fetal defects was evident. Conclusions: Spontaneous abortion risk in alemtuzumab-treated MS patients was comparable to the general population. No patterns in fetus/infant SAEs emerged. A new pregnancy registry will collect prospective data. Background: The Expanded Disability Status Scale (EDSS)-Plus is a composite endpoint developed to assess disability in ambulatory and/or upper limb function or EDSS in patients with progressive MS and is the primary endpoint of the ASCEND study of natalizumab in SPMS. Objectives: Post-hoc analysis to determine the effect of natalizumab on EDSS-Plus in RRMS patients from AFFIRM. Methods: EDSS-Plus was defined as progression of disability in ≥1 of 3 measures: EDSS increase ≥1 point (0<baseline ≤5.5) or ≥1.5 point (baseline=0) or ≥0.5 point (baseline ≥6.0); or ≥20% increase from baseline in Timed 25-Foot Walk time; or 3) ≥20% increase in 9-Hole Peg Test time, confirmed at 6-months.
P-32 Pregnancy Outcomes in the
P-33 Effect of Natalizumab on Progression of Disability in RRMS Patients
Sensitivity analyses included progression in ≥2 measures. The proportion of progressors were compared (natalizumab, n=627; placebo, n=315). Results: Natalizumab reduced the hazard of 6-month confirmed progression on EDSS-Plus by 42% (natalizumab 21%, placebo 31%; HR=0.58, P<0.0001). Placebo group progression was more common on EDSS (23%) than on T25FW (14%) or 9HPT (7%); progression on T25FW or 9HPT was driven by subjects with baseline EDSS>3 (23% and 12%, respectively) . Natalizumab also reduced the hazard of EDSS-Plus progression on ≥2 measures by 63% (natalizumab 3%, placebo 9%; HR=0.37, P=0.0006). Conclusions: While progression on EDSS-Plus was more sensitive than EDSS alone, particularly in patients with baseline EDSS>3, and significant treatment effects of natalizumab were observed, the utility of EDSS-Plus in RRMS remains to be determined, although it might have utility in RRMS patients with higher baseline EDSS who are at higher risk of conversion to SPMS. MSCs are self-replicating cells which can play a role in differentiating in multidirectional pathways, such as osteoblasts, chondrocytes, myocytes, marrow stromal cells, tendon-ligament fibroblasts, adipocytes and neural cells. Methods: We studied recent (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) clinical trials and review articles of stem cell therapy for multiple sclerosis to achieve to the best adult stem cell type and the most effective and safest route in order of managing them.In this article we will first provide an overview of the cell sources for, proposed mechanisms that contribute to the beneficial effects of stem cell transplantation and the ideal route and/or timing of stem cell-based therapies for MSC. Results: It was found 7 clinical trials (table 1) .In some studies we detect critical adverse events that has been indicated some types of SCs act as carcinogen factors. According to our researches, the best stem cell to transfer MS patients was mesenchymal stem cells and injecting intravenously is the best way to administrate. By this goals we prevent from meningeal irritation that will happened in intrathecally administration. Conclusion: Overall, we recommend intravenous MSCs as the best kind of stem cell therapy for autoimmune disorders like MS. It's clear that more studies should be done to prove efficacy and safety of these therapeutic approaches.
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Multiple Sclerosis Journal 2015; 21: (6) 799-838 msj.sagepub.com Multiple sclerosis (MS) is a chronic disease of the central nerve system (CNS) primarily affecting young people and the pathogenesis of MS. The CNS preserves a potent antioxidant defense mechanism to scavenge reactive oxygen species (ROS). Experimental autoimmune encephalomyelitis (EAE) is a convincing animal model of MS and the immunopathogenic mechanisms of EAE is attributed to T-cell-mediated inflammatory disease of the CNS and activated T cells recruit invading inflammatory cells like macrophages and stimulate astrocytes and microglia in situ, consequently secreting icytokines, chemokines, and toxic molecules, in terms of glutamate, nitric oxide (NO) and/or ROS, contributing to axonal damage, followed by complement activation or antibody-mediated phagocytosis of axons leading to demyelination and axonal injury eventually. In brain tissue of MS patients, expression of antioxidants was detected and enhanced in the lesions, indicating the essence of oxidative stress. Thus ROS believably play a role of distinct pathological processes on MS. Antioxidants may inhibit the development and progression of MS lesions. Therefore, antioxidant therapy may represent a striking treatment of MS.
In this review we summarize and discuss the immumodulation and potential therapeutic effects and the novel strategies of antioxidants such as Erythropoietin (EPO), melatonin, α-tocopherol (vitamin E), and α-lipoic acid (ALA) for MS treatment. 
Poster Session 6 NMO Epidemiology
Results:
The overall crude prevalence of NMO among the Caucasian population living in Isfahan province was 1.9/100,000, 95% CI, 1.6-2.3/1000000. The mean age at the onset of the disease was 30.1 ± 10.1 (range: 6.5-60, median: 28) years old. Fiftyseven patients had monophasic NMO while 38 patients had relapsing NMO. Conclusions: Result of our study (that is the largest case series from Western Asia to our knowledge), shows a similar prevalence of NMO in Isfahan comparing to other Caucasian populations; however some differences existed in the clinical and demographic features of the disease in our cohort. In comparison with western countries it seems Iranian NMO patients have a more benign course. Background: Neuromyelitis optica (NMO) has long been considered as a subtype of Multiple Sclerosis (MS) due to the similarities between the clinical presentations. NMO cases have been reported from different regions of the world and several lines of evidence are indicative of a racial predilection for NMO. Objective: In this study, for the first time, we aimed to provide a comprehensive review regarding the incidence and prevalence of NMO across the World. Methods: A comprehensive literature search was performed using Pubmed, Embase, and, Web of Science. We also did manual search of reference lists from primary articles and relevant reviews. Results: A total of 9 articles met the inclusion criteria and were reviewed in this study. Incidence data were found in four studies and ranged from 0.053 per 100,000 per year in Cuba to 0.08 in Mersey side of UK. Prevalence was reported in all studies and ranged from 0.51 per 100,000 in Cuba to 4.4 in Southern Denmark with higher female preponderance (ranged from 2.27 to 4.5). Isfahan, Iran with the mean age of onset of 30 had the lowest and south east Wales with 39.5 had the highest mean age of onset. Conclusions: Despite increasing tendency to epidemiological study on NMO, prevalence and incidence rate in numerous countries has not been published yet. Furthermore most of the studied areas only reported the regional rate but not the whole country. Few studies report the anti AQP-4 antibodies for patients. More studies needed to explore further information about epidemiology of NMO. Results: There were 418 patients with IIDCDs categorized as MS (n=132), clinical isolated syndrome (CIS) (n=32) and neuromyelitis optica (NMO) (n=254). The prevalence of IIDCDs was 0.648 per 100,000 and the incidence rate was 23.0 per 100 person-year. The median EDSS of patients with MS, CIS, or NMO was 3.0, 2.5 or 3.5, respectively. There were 78% (n=326) receiving immunotherapy. The MPR of IFN-β (91%) was higher than azathioprine (62%), while persistence of IFN-β was 50.5%. Treatment for neuropathic pain was the most frequent symptomatic treatment (79%, n=330).
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Multiple Sclerosis Journal
Conclusion:
This was the first study on the prevalence of IIDCDs in Thailand. Compared to previous studies in Asia, the prevalence was low whereas the incidence rate was considerably high. The adherence in immunotherapy was high, while persistence was quite low for IFN-β. Background: The systemic study of lesion localization in vivo NMO models has never been studied sufficiently. Objective: To study the lesion localization of passive transfer NMO-IgG model in Lewis rats. Methods: NMO-IgG was purified from NMO patients serum. Purified IgG with complement inactivated by 56℃ 30 minutes were used for this study. 8 female Lewis rats (8～10 weeks of age) were immunized with an encephalitogenic mixture containing guinea pig brain myelin basic protein in complete Freund's adjuvant for the purpose of breaking down blood brain barrier. Then the rats were infused 20mg of purified NMO-IgG intraperitoneally at the onset of tail paresis or body weight loss more than 10mg/day. Then we examined the parafin sections histopatholigically within 3days from the injection. Results: Vasculocentric AQP4 loss were found in cerebral white matter near ventricles (6/7 cases), hypothalamus (3/7 cases), brain stem (8/8 cases), optic chiasma (3/6 cases), optic tract (2/6 cases) and spinal cord (8/8), but never observed in cerebral and cerebellar gray matter. AQP4 loss was outstandingly observed around gray matter adjacent to border between gray matter and white matter in spinal cord lesions as well as hypothalamic or chiasma lesions. Spinal cord lesions were severe especially in lumbar cords, -but there is no marked demyelination as previously reported. Conclusions: AQP4 loss in this model is compatible with the lesion distribution in NMO patients. Multiple Sclerosis Journal 2015; 21: (6) 799-838 msj.sagepub.com mechanism of neuropathic pain in atopic myelitis remains to be elucidated. Objective: To reproduce neuropathic pain/tactile allodynia in animals by inducing atopic disease. Methods: We induced atopic diathesis and bronchial asthma in C57BL/6J mice (age, 6 weeks) by intraperitoneal injection of ovalbumin (OVA, 50 μg) and aluminum hydroxide (Alum, 2 mg) once a week (O+A group) for 3 weeks. As control, PBS or Alum was injected instead of O+A. Bronchial asthma was induced by further inhalation of OVA (2.5 mg/mL) after O+A or PBS/A injection for 4 consecutive days. We studied tactile allodynia using von-Frey filaments. Spinal cord and lungs were immunohistochemically examined. Astrocyte activation was assayed by measuring the numbers of cells expressing S100β, a reliable marker of astrocyte activation. Results: O+A injection with OVA inhalation produced eosinophil infiltration in the lung. The O+A group showed marked tactile allodynia of hind limbs compared with the PBS/A group when stimulated with 0.04 g and 0.07 g filaments. The numbers of S100β-positive cells were significantly increased in the dorsal horns of the lumbar spinal cord in the O+A group than PBS/A group. Conclusion: Peripheral atopy can induce tactile allodynia/neuropathic pain and astrocyte activation in the spinal cord. Astrocyte activation may be related to emergence of neuropathic pain in atopic conditions.
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Case Presentation: MS Tumefactive demyelinating disease may present atypical imaging which mimics brain tumor. Despite MRI, it is difficult to differentially diagnose tumefactive demyelination. A 43-year-old Korean male presented with a 7-day history of right-side clumsiness. Brain MRI with gadolinium enhancement showed a large, round left frontoparietal lobe lesion with a ring pattern. Glioma or lymphoma was suspected. A 45-year-old woman presented with a 2-week history of vertigo, tinnitus and mild headache. Brain MRI with gadolinium enhancement revealed a white matter mass in the right temporal lobe with slightly peripheral multifocal abnormal signals. Brain biopsy revealed that these were not brain tumors, but rather tumefactive demyelinating lesions. This clinical, radiological and pathological report confirms that the demyelinating process should be considered in the differential diagnosis of tumor-like brain lesions. In conclusion, tumefactive demyelination is an uncommon cause of neurological symptoms. MRI, MRS or PET images can be useful diagnostic tools, and can spare patients brain biopsy.
P-60 Atypical Multiple Sclerosis in A 57-year-old Man as Chronic Lymphocytic Inflammation with Pontine Perivascualr Enhancement Responsitve to Steroid (CLIPPERS)
An-Chih Chen Department of Neurology, Chung Shan Medical University Hoispital, Taichung, Taiwan Background: Chornic lymphocytic inflammation with pontine perivascular enhancement(CLIPPERS) is a newly defined inflmmatory CNS disorder since 2010. However, it remain many debates and the symptoms was overlapping with multiple sclerosis(MS). Objective: A 57-year-old previously healthy man had asymmetric numnbess and weakness for 1 month. He came to our hospital for falling down due to weakness. Physical examination revealed dysarthria, left central facial palsy and muscle power 4 points in left side limbs. Brain MRI showed multiple asymmetrical long T2 and enhancing lesions in brain stem. CSF studies showed lymphocytic pleocytosis, glucose:55mg/dL and protein:102 mg/dL. Optic neuritis was also found. Autoimmune and infection titers were all negative. Methods: Methylprednisolone(MTP) pulse therapy was prescribed with dosage 1g/day for 5 days. The sympotms had dramatic improved. After the MTP pulse therapy, no immunosuppressant agent was used. Three days later, he felt the numbness developed again. Two weeks later, objective weakness developed. Following brain MRI showed newly long T2 lesion in brain stem and CSF studies showed inflammation as previous study. The second MTP pulse therapy started and symptoms improved again. CLIPPERS syndrome was suspected. Beta-inteferon and prednisolone(40mg/ day) was prescribed after pulse therapy. Results: After continuous steroid, the neurologic deficit was stationary. However, hyperglycemia developed in the next weeks.
Conclusion:
The CLIPPERS syndrome might be a varient of multiple sclerosis. It was differience from MS from age and gender. Steroid should be continued after MTP pulse therapy. Following immunosuppressant should replace the steroid to prevent the side-effects. Introduction: Several studies reported that patients with lateonset MS (LOMS) were more likely to have motor and cerebellar presentations, a more progressive course and a worse prognosis than patients with earlier onset disease. However, the clinical profile of LOMS was not determined. Case: A 71-year-old woman was admitted with left 6 th nerve palsy. Brain MRI showed multiple chronic ischemia with a small diffusion restriction lesion in right dorsal medulla oblongata. Aspirin was prescribed with a diagnosis of stroke. After 6 months later, she visited our hospital with right shoulder and forearm paresthesias and right hemiparesis. Brain MRI showed multifocal T2 hyperintensity lesions in both centrum semiovale, corpus callosum, both PVWM, brain stem, and left cerebellum, especially callososeptal interface distribution combined with multiple enhacement. Cervical MRI revealed paracentral short segment myelitis at C2-3.
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A 61-year-old man was admitted with right optic neuritis. Brain MRI showed enhancement of right optic nerve and focal ill-defined T2 hyperintense lesions in subcortical white matter of both inferior frontal gyrus and right cerebellar peduncle with focal enhancing lesions.
Serological study for autoimmune disorder and AQ-4 antibody was all negative in two patients. Steroid pulse treatment was done and their neurological deficit was nearly fully recovered. Finally, a 71-year-old woman was diagnosed as clinical definite MS and a 61-year old man was diagnosed as CIS with brain lesion compatible with MS. Conclusion: One of our patients was initially diagnosed as stroke, so the frequency of initial misdiagnosis might be high in the LOMS patients. Background: Multiple sclerosis is classically characterized by a relapsing-remitting course due to lesions in many parts of the CNS, There is, however, a small group of patients whom the course of the illness is progressive from onset. Objective: To report primary progressive multiple sclerosis case in Jakarta Methods: Case report Results: A 27-year-old man was admitted to our hospital because of progressive blurred vision since 10 months ago. Patient also complains about dizziness and hard to coordinate his movement since 4 months ago. Patient's visual acuity is 3/60 for right eye and 4/60 for left eye. Neurological examination revealed rotatoar nistagmus and abnormal finding in romberg, finger to nose, fast pointing, knee to heel and rebound phenomena test. Brain MRI shows multiple hyper intense lesion at cervical, brain stem, cerebellum, periventricle white matter, juxta/ subcortical and right thalamus with dissemination in space and time fullfil the Multiple Sclerosis' criteria. Visual Evoked Potential shows demyelination type partial block at both eye's visual tract. Cerebrospinal fluid analysis shows normal cell count, normal glucose ratio, increased protein level and positive oligoclonal band result. Patient received methylprednisolon in three phases 1x16mg orally for 6 days, 1x1000mg intravenously for 3 days and 1x1000mg intravenously for 2days. Expanded Disability Status Scale (EDSS) for this patient is 6.0. After receiving that high dose steroid therapy, the visual acuity showed no improvement. Conclusions: Patients with multiple sclerosis who develop progressive from onset without relapses or remissions pose difficulties in diagnosis, monitoring of disease activity and treatment. The prognosis for this group of multiple sclerosis is poor. Background: As a second-line drug for multiple sclerosis (MS), fingolimod is used to treat patients with poor response to interferon-beta in Korea. There are some animal studies about beneficial effect of fingolimod in severe atopic dermatitis (AD). We describe a patient with relapsing-remitting MS, who suffered from severe AD and frequent relapses despite the interferon-beta treatment, simultaneously responded to fingolimod. Case: A19-year-old man suffering from severe AD more than 10 years, experienced left hand weakness, hypethesia and paresthesia that lasted three days and his attack symptoms were spontaneous resolved two years ago. Two months later, he had relapse in cervical myelitis. After high dose intravenous methylprednisolone (IVMP) therapy, his symptoms were recovered slowly over one month and he began receiving interferon-beta therapy. However two months later, he had left hemiparesis and 8 months later, had another attack of right arm weakness and bilateral leg paresthesia. Each relapse was treated with IVMP and recovered. We switched to fingolimod with interferon-beta because relapse occurred twice in a short period of time due to lack of effect. After fingolimod therapy, he had no further relapse over 14 months and no MRI activity. Interestingly, his severe AD was improved dramatically as the same time.
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Conclusion:
We report a case of good response to fingolimod for severe AD and highly active MS. When considering our case, fingolimod is effective therapy for patient with poor response to interferon-beta and good candidate for treatment of intractable AD.
P-64 Efficacy of Fingolimod for Recurrent Spinal Cord Lesions in A Case of Multiple Sclerosis
Ozawa T, Warabi Y, Isozaki E Department of Neurology, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan Background: Interferon beta (IFNβ) therapy, a first-line diseasemodifying therapy (DMT) for multiple sclerosis (MS), may not be efficacious in some patients. Recently, second-line DMTs have been introduced in Asian countries. Although opticospinal MS is reported as a racial modification of MS in Asian populations, the efficacy of DMTs for Asian-type MS has only limited supporting evidence. Objective: We report the case of a patient with conventional MS who had recurrent spinal cord lesions. She did not respond to IFNβ treatment, but she was successfully treated with fingolimod. Case: A 31-year-old Japanese woman visited us because of paresthesia of both her legs. She was found to have two spinal cord lesions and one cerebral lesion. Oligoclonal IgG bands were detected but not the anti-aquaporin-4 antibody. We diagnosed her as having clinically isolated syndrome of MS, and we started IFNβ-1a therapy. Eight months later, she developed a recurrent spinal cord lesion, and she was diagnosed as having MS. Subsequently, she had eight relapses, including six relapses in the spinal cord, within the next two years and two months. IFNβ-1a was stopped and tacrolimus was tried but was not efficacious. Then, fingolimod was started with minimal side effects. No relapse had occurred over the subsequent one year and five months. Background: Neuromyelitis optica (NMO) is a CNS demyelinating disease characterized by recurrent attacks of optic neuritis and transverse myelitis. The aim of treatment is to restore neurological deficit and maintain remission. High-dose methylprednisolone is primary therapy for acute attacks, and plasma exchange (PE) is helpful for those unresponsive to steroid. For long-term remission, various immunosuppressants are recommended. We are to describe a patient with NMO, who is refractory to immunosuppression, and finally requiring mitoxantrone. Case: A 40-year-old woman developed right optic neuritis at age 28. After the first event, she had several attacks involving optic nerves, medulla and spinal cord. Under the diagnosis of multiple sclerosis, she achieved remission with interferon beta-1b for 10 years. But, she experienced 10 cluster-attacks for next three years and 6 for recent one year. All attacks were managed by high dose methylprednisolone or PE with only partial improvement. She was re-diagnosed as NMO on the presence of anti-NMO antibody, and she started azathioprine and later changed to mycophenolate due to refractoriness. Nevertheless, she repeated relapses and finally became near-blind and wheelchair-bound state. She decided to use mitoxantrone. After one cycle, she is currently free of attacks except for a short time of leucopenia. Conclusion: NMO has only few treatment options for long-term remission except for known immunosuppressants. Our patient experienced cluster-attacks after relapse-free time despite of immunosuppression. Mitoxantrone finally seemed to be successful for stopping relapses. It might be for a possible option for patients with NMO, who are refractory to classical immunosuppression.
Conclusions
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Case Presentation: MS Mimics Background: Primary CNS vasculitis is an uncommon disease in which lesions are limited to the brain and spinal cord. A variety of neurologic insults may cause CNS vasculitis, including infection, malignancy, ionizing radiation, cocaine ingestion, and autoimmune disease. Spinal cord involvement has been documented much less frequently than intracranial involvement. We report a case spinal symptoms developed before cerebral symptoms. Case: A 59-year-old man was admitted our hospital due to further evaluation and management of cervical myelitis with CNS infection. At first attack, MRI revealed increased T2-weighted signal from pons to C5 level. His tentative diagnosis was NMO spectrum disorder with negative anti-AQP4 antibody. Two months later, he developed drowsy mentality and CSF analysis showed WBC; 250 cells/mm 3 (neutrophil 90%), glucose; 55 mg/dL and protein; 84.6 mg/dL. He was treated with antibiotics under the impression of bacterial meningitis and transferred to our hospital. He showed gradual improvement. However, 2 months later, he developed drowsy mentality with high fever. Brain MRI showed increased T2-weighted signal in left cerebral peduncle, thalamus, BG, right thalamus, both pericallosal area, and left temporal lobe with mild enhancement. CSF study showed leukocytosis (WBC: 1,460 cells/ mm 3 , neutrophil: 82%), low glucose level (19 mg/dL, serum: 104) and high protein level (288 mg/dL). Brain biopsy revealed: (1) vasculitis with dense perivascular infiltrates of T lymphocytes and
